Esophageal Squamous Cell Carcinoma
Conditions
Brief summary
Comparative analysis of patients with resectable locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy combined sintilimab versus neoadjuvant chemoradiotherapy.
Detailed description
The research process is divided into three stages: firstly, the stage of screening period for 14 days. Qualified subjects will enter the treatment period after completion of screening examination and evaluation. And then, the stage of treatment period: Experimental group (group A) received sintilimab combined with neoadjuvant chemotherapy regimen: preoperative neoadjuvant, sintilimab (D1 administration) combined with chemotherapy (TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). The experimental group (group B) received neoadjuvant sintilimab combined concurrent chemoradiotherapy: preoperative sintilimab (D1 administration) combined with neoadjuvant concurrent chemoradiotherapy. Chemotherapy regimen: TP regimen: albumin-paclitaxel + carboplatin, D1 administration, 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Radiotherapy regimen: according to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week. And the control group (group C) received neoadjuvant chemoradiotherapy and the regimen was similar with group B. Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patient without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed. Lastly, the stage of postoperative assistance, the researchers selected postoperative treatment according to the guidelines for the diagnosis and treatment of esophageal cancer. Patients were followed up for efficacy and safety within 90 days after surgery, once every 3 months for 2 years and once every 6 months for 2-5 years.
Interventions
DRUGChemotherapy
Neoadjuvant chemotherapy with TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W).
DRUGSintilimab
Sintilimab: D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W)
RADIATIONradiotherapy
Radiotherapy: According to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week.
Sponsors
Peking University Cancer Hospital & Institute
Tianjin Medical University Cancer Institute and Hospital
Hebei Medical University Fourth Hospital
Anhui Provincial Hospital
The First Affiliated Hospital with Nanjing Medical University
Anyang Tumor Hospital
Shantou Central Hospital
Innovent Biologics (Suzhou) Co. Ltd.
GeneCast Biotechnology Co., Ltd.
Sichuan Cancer Hospital and Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 18 to 75, both sexes; 2. Patients with histologically confirmed locally advanced (cT1N2-3M0 or cT2-4aN0-3M0) thoracic esophageal squamous cell carcinoma (8th UICC-TNM stage); 3. Cervical contrast-enhanced CT showed no suspicious metastatic lymph nodes. Imaging examination showed no systemic metastasis. 4. R0 resection is expected to be achieved; 5. Physical state ECOG 0 \ 1; 6. No previous antitumor therapy for esophageal cancer, including chemotherapy, radiotherapy (including radiotherapy planned during the study), hormone therapy, and immunotherapy; 7. Measurable lesions (according to RECIST v1.1); 8. There was no operation contraindications in the evaluation of various organ functions before operation; 9. The following laboratory tests confirm that the bone marrow, liver and kidney functions meet the requirements for study participation: * Hemoglobin ≥90g/L; * White blood cell count ≥ lower limit of laboratory normal; * Neutrophil absolute value (ANC) ≥1.5×109/L; * Platelet count ≥100×109/L; Total bilirubin ≤1.5× upper limit of normal (ULN); * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; * Prothrombin time ≤16 seconds and international normalized ratio ≤1.5×ULN; Creatinine ≤1.5×ULN or Cr clearance ≥50 mL/min (calculated using Cockcroft-Gault formula); 10. Fertile women must consent to use effective contraception (e.g. intrauterine devices, birth control pills, or condoms) during the study medication period and within 60 days of the last study medication, have a negative serum pregnancy test within 7 days before study enrollment, and be non-lactating; Men agree that they must use effective contraception during the study medication period and for 60 days after the last study medication; 11. The informed consent must be understood and signed.
Exclusion criteria
Patients who met any of the following criteria were excluded from the study: 1. Malignant tumors other than esophageal cancer (cured localized tumors, including cervical carcinoma in situ, skin basal cell carcinoma and prostate carcinoma in situ, were not excluded) had occurred within 5 years before randomization; Prostate cancer patients receiving hormone therapy with DFS for more than 5 years were not excluded). 2. Patients with high blood tendency who had a history of gastrointestinal bleeding within 6 months before randomization, or had coagulopathy at the time of enrollment, or were receiving thrombolysis or anticoagulant therapy; 3. Severe cardiovascular and cerebrovascular diseases: • New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina, myocardial infarction, poorly controlled arrhythmias, or cerebrovascular accidents within 12 months before randomization. LVEF (left ventricular ejection fraction) \<50% on echocardiography. Corrected QT interval (QTc) \>480ms (calculated using Fridericia's method; if QTc was abnormal, three consecutive tests were performed at 2 min intervals and the mean value was taken). Medically difficult to control hypertension (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100mmHg) (based on the average of ≥2 measurements). • A previous hypertensive crisis or hypertensive encephalopathy. 4. Previous history of interstitial lung disease or pneumonia requiring steroid treatment at enrollment; 5. Had active tuberculosis at the time of randomization, or had received anti-tuberculosis therapy within 1 year before randomization; 6. Asthma at random requiring intermittent use of bronchodilators or other medical interventions; 7. Patients with infectious diseases requiring systemic treatment (oral or intravenous administration) within 4 weeks before randomization; for active hepatitis, effective treatment was required before enrollment; 8. Severe unhealed wounds, active ulcers, and untreated fractures at random; 9. Combined with other inoperable conditions; 10. The previous operation resulted in the inability to use stomach instead of esophagus to reconstruct the digestive tract in this operation; 11. Was receiving systemic steroid therapy (more than 10mg of prednisone daily or equivalent) or other immunosuppressive agents during the 2 weeks prior to randomization; 12. Severe allergy to chemotherapy drugs (albumin paclitaxel or cisplatin) or any monoclonal antibody; 13. Has had an active autoimmune disease requiring systemic treatment (i.e., immunomodulatory drugs, corticosteroids, or immunomodulatory drugs) in the past 2 years; However, replacement therapy (e.g., thyroxine, insulin, or replacement therapy with physiologic corticosteroids for adrenal or pituitary insufficiency) is not considered systemic therapy and is allowed for use and enrollment; 14. Previous organ transplant recipients; 15. If HBsAg(+) and/or HBcAb(+) are required, HBV DNA must be \< 500IU/mL. (If the lower limit of the local center's minimum detectable value is higher than 500IU/mL, after discussion with the sponsor, Enrollment was determined on a case-to-case basis) and continued to receive effective anti-HBV therapy that was already in use during the study period, or entecavir or tenofovir therapy was started prior to study medication; 16. Hcv-rna testing should be performed if HCV antibody is positive, and HCV-RNA\>10\^3 copy number /mL should be excluded; 17. Co-infection with HIV; 18. In the judgment of the investigator, there are other circumstances that are not suitable for participating in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathology complete response rate, pCR | 3 months after the surgery | Definition of pathology complete response is no cancer cell, including lympho nodes which corresponds with tumor regression score 0 definition of pathologic response is as follows. Tumor regression score Grade 0 and 1 will be defined as responder and 2 and 3 will be considered as non-responders. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of R0 resection | 3 months after the surgery | Measure the rate of R0 resection with all margins microscopically clear. |
| Treatment related adverse event, TRAE | 3 months after the surgery | The TRAE defined as the proportion of participants who have treatment-related adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Event, Version 4.0 (CTCAE v4.0). |
| Events Free Survival, EFS | Through study completion, an average of 1 year. | Event-free survival was defined as the time from the date of randomization to the date of the first documented non-fatal event (worsening cardiac function, hospitalization for congestive heart failure, liver function impairment, liver cirrhosis, transformation to AML, as defined in the protocol), or death, whichever occurred first. Participants who did not experience a non-fatal event as of the time of data cut-off (end of study), as well as participants who did not experience a non-fatal event and stopped study participation before the data cut-off, were censored as specified in the protocol. |
| Overall Survival,OS | 5 years after inclusion | Overall survival was the duration from the start of study treatment to death. |
| Major Pathological Remission rate, MPR | 3 months after the surgery | The residual tumor after neoadjuvant treatment ≤ 10% residual tumor lesion in surgical specimen compared to baseline. |
| Disease Control Rate, DCR | 3 years after inclusion | he Disease Control Rate (DCR) will be defined as the proportion of patients with a best overall response of CR, PR or Stable Disease (SD) (RECIST V1.1) 2 months after randomization |
| Objective Response Rate, ORR | 3 years after inclusion | The Objective Response Rate (ORR) will be defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR) (RECIST V1.1) |
| Circulating tumor DNA, ctDNA | Before neoadjuvant therapy, before surgery, 1, 6, 12, 18, 24 months after surgery | Blood will be drawn and tested for ctDNA |
| disease-free survival, DFS | 5 years after inclusion | DFS is defined as the time interval between the date of random assignment and the date of the first documented evidence of relapse at any site or death related to cancer (including toxicity), whichever occurred first. |
Countries
China
Contacts
Primary ContactYongtao Han, M.D.
Outcome results
None listed